Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|November 1, 2016
Dendritic cell and cancer immune checkpointTerufumi Kubo, Yoshihiko Hirohashi, Toshihiko Torigoe
Cureus|November 7, 2023
Severe Acute Pancreatitis Rapidly Developed Into Pulmonary Edema and Diffuse Alveolar Hemorrhage Leading to Respiratory Failure: An Autopsy CaseMichiko Hosaka, Terufumi Kubo, Takeshi Matsuoka, et al.
Auris, Nasus, Larynx|October 27, 2019
Occult carcinoma confirmed to be a diffuse sclerosing variant of papillary thyroid carcinoma with unusual immunohistochemical features: A pitfall of clinicopathological diagnosisTerufumi Kubo, Noriaki Kikuchi, Shinichi Shiina, et al.
Biochemical and Biophysical Research Communications|December 3, 2014
Tight junction protein claudin-4 is modulated via ΔNp63 in human keratinocytesTerufumi Kubo, Kotaro Sugimoto, Takashi Kojima, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|October 22, 2008
p63 induces CD4+ T-cell chemoattractant TARC/CCL17 in human epithelial cellsTerufumi Kubo, Shingo Ichimiya, Akiko Tonooka, et al.
Hinyokika Kiyo. Acta Urologica Japonica|November 4, 2022
[Usefulness of Immunostaining Scoring for Predicting Response to Single-Agent Nivolumab in Patients with Metastatic Renal Cell Carcinoma]Takahito Wakamiya, Terufumi Kubo, Shimpei Yamashita, et al.
Pathology International|July 21, 2016
Peptide vaccination therapy: Towards the next generationTomohide Tsukahara, Yoshihiko Hirohashi, Takayuki Kanaseki, et al.
Immunological Medicine|September 20, 2021
Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapyTerufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, et al.
Scientific Reports|June 23, 2022
Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patientsToshiki Kijima, Terufumi Kubo, Daisaku Nishihara, et al.
Human Vaccines & Immunotherapeutics|February 11, 2021
Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapyTerufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, et al.
Pageof 12